Literature DB >> 34741320

Molecular targets of psychedelic-induced plasticity.

Alaina M Jaster1,2, Mario de la Fuente Revenga1,3, Javier González-Maeso1.   

Abstract

Psychedelic research across different disciplines and biological levels is growing at a remarkably fast pace. In the prospect of a psychedelic drug becoming again an approved treatment, much of these efforts have been oriented toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic interest. Considering the central role of the serotonin 5-HT2A receptor in the distinct effects of psychedelics in human psyche, neuropharmacology sits at the center of this debate and exploratory continuum. Here we discuss some of the most recent findings in human studies and contextualize them considering previous preclinical models studying phenomena related to synaptic plasticity. A special emphasis is placed on knowledge gaps, challenges, and limitations to evaluate the underpinnings of psychedelics' potential antidepressant action.
© 2021 International Society for Neurochemistry.

Entities:  

Keywords:  5-HT2A receptor; GPCR; LSD; hallucinogens; psychedelics; serotonin

Mesh:

Substances:

Year:  2021        PMID: 34741320      PMCID: PMC9068831          DOI: 10.1111/jnc.15536

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.546


  93 in total

1.  Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

Authors:  Javier González-Maeso; Noelia V Weisstaub; Mingming Zhou; Pokman Chan; Lidija Ivic; Rosalind Ang; Alena Lira; Maria Bradley-Moore; Yongchao Ge; Qiang Zhou; Stuart C Sealfon; Jay A Gingrich
Journal:  Neuron       Date:  2007-02-01       Impact factor: 17.173

2.  Trial of Psilocybin versus Escitalopram for Depression.

Authors:  Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt
Journal:  N Engl J Med       Date:  2021-04-15       Impact factor: 91.245

3.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.

Authors:  Kelly A Jones; Deepak P Srivastava; John A Allen; Ryan T Strachan; Bryan L Roth; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

4.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.

Authors:  Danuta Marona-Lewicka; Ronald A Thisted; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

Review 5.  The molecular neurobiology of depression.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

6.  The HIV antiretroviral drug efavirenz has LSD-like properties.

Authors:  Michael B Gatch; Alexey Kozlenkov; Ren-Qi Huang; Wenjuan Yang; Jacques D Nguyen; Javier González-Maeso; Kenner C Rice; Charles P France; Glenn H Dillon; Michael J Forster; John A Schetz
Journal:  Neuropsychopharmacology       Date:  2013-05-24       Impact factor: 7.853

7.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Authors:  Rr Griffiths; Wa Richards; Mw Johnson; Ud McCann; R Jesse
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

8.  Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo.

Authors:  Cullen L Schmid; Kirsten M Raehal; Laura M Bohn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

9.  Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.

Authors:  Charles D Nichols; Efrain E Garcia; Elaine Sanders-Bush
Journal:  Brain Res Mol Brain Res       Date:  2003-03-17

10.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Authors:  Alan K Davis; Frederick S Barrett; Darrick G May; Mary P Cosimano; Nathan D Sepeda; Matthew W Johnson; Patrick H Finan; Roland R Griffiths
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

View more
  1 in total

Review 1.  Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Authors:  David E Olson
Journal:  Biochemistry       Date:  2022-01-21       Impact factor: 3.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.